Today: 7 February 2026
Subscribe
Browse Category

Financial Forecasts News 23 December 2025 - 24 December 2025

Apple Stock (AAPL) News, Forecasts and Analyst Outlook for December 24, 2025: AI “Siri 2.0” Catalyst, App Store Regulation, and What’s Next in 2026

Apple Stock (AAPL) News, Forecasts and Analyst Outlook for December 24, 2025: AI “Siri 2.0” Catalyst, App Store Regulation, and What’s Next in 2026

Apple Inc. stock (NASDAQ: AAPL) is trading through a holiday-thinned session on Wednesday, December 24, 2025, with U.S. equities markets closing early at 1:00 p.m. ET for Christmas Eve. New York Stock Exchange+1 In early trading, AAPL hovered around $272 with light volume—typical for a shortened session and the final stretch of year-end positioning. What makes Apple stock especially interesting heading into 2026 is that the near-term story isn’t just “iPhone and Services” anymore. It’s turning into a three-way tug-of-war between: Below is a comprehensive, publication-ready roundup of the most relevant Apple stock headlines, forecasts, and analyst takes investors are
24 December 2025
··
Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Dec. 24, 2025 — Novo Nordisk A/S (NYSE: NVO) has snapped back into the market’s spotlight this week after U.S. regulators cleared a pill version of its blockbuster obesity drug Wegovy—an approval that investors and analysts see as a pivotal moment in the fast-evolving GLP‑1 weight-loss race. But the story driving Novo Nordisk stock today is bigger than a single FDA decision: it’s also about pricing and coverage policy in the U.S., and a global expansion battle—especially in India—where branded GLP‑1s are colliding with the prospect of cheaper generics in 2026. Novo Nordisk+2Reuters+2 NVO shares have been trading around the
24 December 2025
···
Strategy Inc Stock MSTR News and Forecasts for December 24, 2025: Cash Reserve Pivot, Bitcoin Pause, and Wall Street Targets

Strategy Inc Stock MSTR News and Forecasts for December 24, 2025: Cash Reserve Pivot, Bitcoin Pause, and Wall Street Targets

December 24, 2025 — Strategy Inc (Nasdaq: MSTR) is spending Christmas Eve with investors debating a simple but loaded question: is the company’s latest move a prudent de-risking… or a sign that the “leveraged Bitcoin proxy” era is maturing into something more complicated? Shares have been volatile this week, trading around the high-$150s as the market digests fresh disclosures showing no new Bitcoin purchases during the latest reporting window and a sharply higher U.S. dollar cash reserve built from equity sales. MarketBeat+2MarketBeat+2 At the same time, Executive Chairman Michael Saylor is trying to reframe the entire investment story—positioning Strategy not
24 December 2025
··
Broadcom (AVGO) Stock News Today, Forecasts and Analysis for Dec. 24, 2025: AI Margins, Tariffs, Insider Moves and Valuation

Broadcom (AVGO) Stock News Today, Forecasts and Analysis for Dec. 24, 2025: AI Margins, Tariffs, Insider Moves and Valuation

Broadcom Inc. (NASDAQ: AVGO) enters Christmas Eve trading with investors still debating the same two questions that have defined the stock’s volatile December: how durable is the AI-driven demand surge—and how much profitability gets sacrificed to capture it? With U.S. equities markets scheduled to close early at 1:00 p.m. ET today, liquidity is thinner than usual, which can exaggerate moves in high-momentum names like Broadcom. New York Stock Exchange+1 As of the latest available quote on Dec. 24, Broadcom shares were hovering around the $349–$350 area, after a strong prior session. MarketWatch Why Broadcom stock is still a headline name
24 December 2025
··
Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute, Inc. (Nasdaq: RZLT) is still in the spotlight on December 24, 2025, after a brutal mid-December selloff tied to its pivotal clinical trial news—and a wave of follow-on analyst downgrades, price-target resets, and investor-law-firm investigations. As of the latest available pricing around $2.42 per share, the stock is off its post-trial lows but remains dramatically below pre-readout levels, leaving investors weighing a simple question with complicated consequences: was sunRIZE a fatal blow, or a detour that shifts the story toward Rezolute’s next late-stage program? MarketBeat+1 Below is a complete, publication-ready breakdown of the current RZLT stock news, forecasts, and
24 December 2025
··
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is in the spotlight on December 24, 2025 after a sharp selloff driven by a major regulatory development: the U.S. Food and Drug Administration recommended that Reviva run an additional Phase 3 trial for its lead schizophrenia candidate, brilaroxazine, before filing a New Drug Application (NDA). SEC+1 Shares were trading around $0.32 after the drop, reflecting how quickly biotech valuations can reprice when timelines and funding needs change—especially for micro-cap clinical-stage companies. StockAnalysis What happened to Reviva Pharmaceuticals stock on December 24, 2025? The core catalyst is a regulatory “reset” of the near-term approval
24 December 2025
···
Canopy Growth (CGC) Stock on Dec. 24, 2025: Schedule III Executive Order, MTL Cannabis Deal, and the Latest Forecasts

Canopy Growth (CGC) Stock on Dec. 24, 2025: Schedule III Executive Order, MTL Cannabis Deal, and the Latest Forecasts

Canopy Growth Corporation (NASDAQ: CGC, TSX: WEED) is ending 2025 with something cannabis stocks haven’t seen in a while: sustained, headline-driven volatility — the kind that can lift prices fast, then yank them back down just as quickly. As of Dec. 24, 2025, CGC was trading around $1.40 in U.S. markets, after closing at $1.40 on Dec. 23 and showing a modest uptick in early premarket indications. StockAnalysis That price tag doesn’t tell the story by itself. December’s story is about policy momentum in Washington, a fresh Canadian acquisition announcement, and a market that’s still trying to decide whether Canopy
24 December 2025
····
Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies Corporation (NASDAQ: DVAX) is the center of the biotech tape on Wednesday, December 24, 2025, after Sanofi announced a deal to acquire the vaccine maker in an all-cash transaction valued at roughly $2.2 billion. The headline number investors are keying on: $15.50 per share in cash—a bid that reframes the near-term outlook for DVAX stock from “earnings and pipeline execution” to “deal timeline and closing risk.” Sanofi+1 Below is what’s driving today’s move, how the market is pricing the deal so far, what Wall Street forecasts looked like before the announcement, and the key dates and risks investors
24 December 2025
···
Nat++West Group Plc Stock (NWG): Buyback Momentum, Evelyn Partners Deal Watch, and What Forecasts Say as of 24 December 2025

Nat++West Group Plc Stock (NWG): Buyback Momentum, Evelyn Partners Deal Watch, and What Forecasts Say as of 24 December 2025

NatWest Group plc stock (LSE: NWG) is heading into the Christmas break sitting close to its best levels in years, with investors balancing three big forces: an ongoing £750 million share buyback, a potential move in UK wealth management via the Evelyn Partners sale process, and a UK interest-rate environment that’s turning more supportive for borrowers—but trickier for bank margins. SEC+2Reuters+2 In holiday-thinned trading on Wednesday, 24 December 2025, NatWest shares were around the 647p level, after touching an intraday high above 651p earlier in the session, according to widely used market data feeds. Investing.com+1 Below is a comprehensive, up-to-date
24 December 2025
···
Lloyds Banking Group (LLOY) Share Price on 24 December 2025: Latest News, 2026 Forecasts, Dividend Outlook and Key Risks

Lloyds Banking Group (LLOY) Share Price on 24 December 2025: Latest News, 2026 Forecasts, Dividend Outlook and Key Risks

Lloyds Banking Group plc stock is heading into the Christmas break with a familiar mix of momentum and mystery: the share price is hovering just below the psychologically loud £1 level, but the 2026 outlook still hinges on one giant unresolved storyline—UK motor finance redress—plus the quieter, slow-burn question of what falling interest rates do to a bank that’s famously UK-heavy. As of 24 December 2025, Lloyds shares were trading around 97.5p, near the top of their 52‑week range (roughly 52p–98p). Investing.com That puts the stock within touching distance of the “penny stock no more?” narrative that’s been building through
24 December 2025
··
UOB Stock Price Today (SGX: U11): Shares Close at S$35.03 on Dec 24, 2025 as 2026 Margin Forecasts Take Center Stage

UOB Stock Price Today (SGX: U11): Shares Close at S$35.03 on Dec 24, 2025 as 2026 Margin Forecasts Take Center Stage

SINGAPORE (Dec 24, 2025) — United Overseas Bank Limited (UOB) shares ended the Christmas Eve session slightly higher, a small but notable outperformer among Singapore’s big three banks during thin, holiday-tilted trading. UOB (SGX: U11) rose 0.1% to S$35.03, even as the Straits Times Index (STI) slipped 0.06% ahead of the festive break. The Business Times+1 The move was modest, but the context matters: bank investors are still pricing a tug-of-war between (1) lower interest rates that can compress margins and (2) capital strength and dividends that continue to make Singapore banks core “income” holdings. And for UOB specifically, that
24 December 2025
··
DroneShield Limited (ASX:DRO) Stock Today: New $6.2m Asia-Pacific Military Contract, Governance Reset, and 2026 Analyst Forecasts (24 Dec 2025)

DroneShield Limited (ASX:DRO) Stock Today: New $6.2m Asia-Pacific Military Contract, Governance Reset, and 2026 Analyst Forecasts (24 Dec 2025)

Sydney | 24 December 2025 — DroneShield Limited stock (ASX:DRO) is closing out 2025 with fresh contract momentum, after the counter-drone specialist disclosed a new $6.2 million Asia-Pacific military contract and reiterated a delivery-and-cash timetable that points mainly into 2026. The announcement lands as investors keep one eye on the order book and the other on a governance clean-up that began after a volatile November sell-off. Company Announcements+2ASX Announcements+2 Below is what we know as of 24.12.2025, what the market is reacting to, and what current analyst targets and valuation narratives imply for DroneShield’s 2026 outlook. What DroneShield announced on
24 December 2025
···
Northern Star Resources (ASX:NST) Stock: Latest News, Analyst Forecasts and Outlook on 24 December 2025

Northern Star Resources (ASX:NST) Stock: Latest News, Analyst Forecasts and Outlook on 24 December 2025

Northern Star Resources Ltd (ASX: NST) is back in the spotlight on 24 December 2025, and the reason is refreshingly simple: gold is doing gold things—namely, smashing records and dragging gold equities higher with it. In Australia, the All Ordinaries Gold sub-index climbed to fresh highs, with large producers including Northern Star Resources rising as much as 1.5% in the session, according to ABC’s market coverage. ABC Meanwhile, Reuters reported spot gold at fresh all-time highs around $4,524/oz, capping a year in which bullion has surged roughly 72%. Reuters Below is a full, publication-ready roundup of what’s driving Northern Star
24 December 2025
···
PLS Group Limited Stock (ASX: PLS) Surges Into Christmas Eve Spotlight: Latest News, Forecasts, and Analyst Outlook on 24 December 2025

PLS Group Limited Stock (ASX: PLS) Surges Into Christmas Eve Spotlight: Latest News, Forecasts, and Analyst Outlook on 24 December 2025

PLS Group Limited stock is back on traders’ radar on 24 December 2025, with the newly rebranded lithium heavyweight (formerly Pilbara Minerals) showing up among the ASX’s most-bought names in a holiday-shortened session. The move lands at a fascinating intersection: a lithium sector that’s been whip-sawed by price volatility, a resources complex being boosted by record-setting metals prices, and a company that’s actively reshaping its story from “single flagship mine” to “portfolio + downstream + Brazil.” On the day, ABC’s Markets Live reported that PLS was among the ASX 200 names seeing the strongest demand, grouped alongside Liontown and other
24 December 2025
··
AbbVie (ABBV) Stock After Hours Today (Dec. 23, 2025): Key News, Forecasts, and What to Watch Before the Market Opens Dec. 24

AbbVie (ABBV) Stock After Hours Today (Dec. 23, 2025): Key News, Forecasts, and What to Watch Before the Market Opens Dec. 24

AbbVie Inc. (NYSE: ABBV) finished Tuesday’s session (December 23, 2025) modestly higher and then held steady in after-hours trading—an important detail heading into a holiday-shortened next session where liquidity can be thin and headlines can move prices faster than usual. Below is what investors are watching tonight: the after-hours tape, the policy backdrop around U.S. drug pricing, and AbbVie-specific developments ranging from pipeline strategy beyond Botox to a late-day legal update tied to Orilissa. AbbVie stock after hours: the numbers investors are tracking AbbVie shares closed Tuesday at $228.79, up roughly 0.4% on the day, and traded slightly higher shortly
24 December 2025
··
Netskope Stock (NASDAQ: NTSK) Slides on Dec. 23, 2025: What’s Driving the Move, Fresh Earnings Context, and Wall Street Forecasts

Netskope Stock (NASDAQ: NTSK) Slides on Dec. 23, 2025: What’s Driving the Move, Fresh Earnings Context, and Wall Street Forecasts

Netskope, Inc. stock is having another “welcome to public markets” moment. In Tuesday’s session (December 23, 2025), Netskope (NASDAQ: NTSK) fell about 5%–6%, with shares last around $18.6 after trading roughly between $18.50 and $19.54. Investing.com+1 That drop stood out because the broader market leaned bullish on the day—U.S. indexes pushed higher as the S&P 500 hovered near record territory. Investors So why is Netskope down today, what’s actually changed since its high-profile September IPO, and what do forecasts and analyst price targets look like right now (as of 23.12.2025)? Here’s the full picture. Netskope stock price today: the Dec.
23 December 2025
···
Target Stock News Today: TGT Slips on Dec. 23, 2025 as Holiday Sales Data, App Outage, and Wall Street Forecasts Shape 2026 Outlook

Target Stock News Today: TGT Slips on Dec. 23, 2025 as Holiday Sales Data, App Outage, and Wall Street Forecasts Shape 2026 Outlook

Dec. 23, 2025 — Target Corporation (NYSE: TGT) stock traded lower Tuesday as investors weighed late-holiday-season execution risks, fresh analyst commentary tied to a recent digital outage, and a broader read-through from U.S. holiday spending data. As of the latest available trade, Target shares were around $94.23, down about 1.0% on the day after opening near $95.25 and trading between roughly $93.80 and $95.39 intraday. The price action comes during a period when Target has been trying to steady results after multiple quarters of negative comparable sales, while simultaneously laying the groundwork for a leadership transition and a strategy refresh
23 December 2025
··
Brown-Forman Stock (BF.B) Slides on Dec. 23, 2025: What’s Driving Jack Daniel’s Maker Today, Plus Analyst Forecasts and Key Levels

Brown-Forman Stock (BF.B) Slides on Dec. 23, 2025: What’s Driving Jack Daniel’s Maker Today, Plus Analyst Forecasts and Key Levels

Brown-Forman Corporation’s Class B shares (NYSE: BF.B) are having the kind of December day investors don’t toast to: the stock is down about 5% in Tuesday trading, sliding to roughly $26.67 after opening near $28.06 and dipping as low as about $26.57. Trading volume is running in the low millions of shares, and the intraday range shows a sharp fade from the morning high near $28.09. markets.businessinsider.com The move extends a short-term downtrend. On Monday (Dec. 22), BF.B closed at $28.10, underperforming the broader market session even as major indexes rose. MarketWatch So what’s going on? The short version: investors
23 December 2025
·
Fermi Inc (FRMI) Stock Today, Dec. 23, 2025: Tenant Funding Deal Fallout, Amazon Rumor Denial, and What Analysts Forecast Next

Fermi Inc (FRMI) Stock Today, Dec. 23, 2025: Tenant Funding Deal Fallout, Amazon Rumor Denial, and What Analysts Forecast Next

Fermi Inc. (NASDAQ & LSE: FRMI) is having the kind of December that turns a “future-of-AI-infrastructure” story into a market stress test. In Tuesday’s trading (December 23, 2025), FRMI was changing hands in the mid‑$8 range—down roughly mid‑single digits on the day—after a turbulent two weeks dominated by one headline: a prospective anchor tenant terminated a $150 million construction-funding agreement tied to Fermi’s Project Matador campus in Texas. MarketBeat+2StockAnalysis+2 The stock’s pullback has been amplified by a second plot twist: Business Insider reported that Amazon was the unnamed tenant behind the terminated agreement, but Reuters reported that Fermi explicitly denied
23 December 2025
··
Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb Company (NYSE: BMY) stock is back in the spotlight on Tuesday, December 23, 2025, as investors weigh a fast-moving U.S. drug-pricing landscape, fresh legal headlines tied to Medicare negotiations, and new analyst commentary on competitive pressure in a key growth product category. At the same time, Bristol Myers is heading into 2026 with a higher dividend, a defined near-term calendar (including a February earnings date), and intensifying debates over whether the stock’s “value” profile is a bargain—or a reflection of policy risk and the post-patent “reset” that still hangs over Big Pharma. BMY stock price today (December 23,
23 December 2025
··
1 … 3 4 5 6 7 … 41

Stock Market Today

Micron stock jumps into the weekend: UBS lifts target to $450 as Nvidia HBM4 doubts surface

Micron stock jumps into the weekend: UBS lifts target to $450 as Nvidia HBM4 doubts surface

7 February 2026
New York, Feb 7, 2026, 11:09 (EST) — Market closed. Micron Technology, Inc. shares finished Friday up 3.08% at $394.69, after trading between $372.87 and $396.65. With U.S. markets shut for the weekend, the stock heads into Monday with investors split between a bullish pricing story and a fresh jab at Micron’s position in AI memory. (Investing.com) Why it matters now: memory has turned into a frontline trade in the AI build-out. Big tech firms including Amazon, Alphabet, Microsoft and Meta are expected to spend more than $630 billion this year as they push deeper into artificial intelligence, putting suppliers
Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Go toTop